Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Macro

Medicare Shakeup: Policy Changes Rattle Big Insurers

by Team Lumida
May 17, 2024
in Macro, News
Reading Time: 4 mins read
A A
0
emergency signage

Photo by Pixabay on Pexels.com

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

  1. Biden administration’s policy changes reduce Medicare Advantage profitability.
  2. Insurers like CVS and Humana face rising costs and declining profits.
  3. Market and regulatory challenges could reshape the future of Medicare Advantage.

What Happened?

The Medicare Advantage landscape has dramatically shifted. Medicare Advantage, a program where the government pays insurers to manage senior care, has been a major profit driver for companies like UnitedHealth Group and Humana. However, the Biden administration’s recent policy changes have altered the payment structures, causing a significant dip in profitability.

CVS Health’s Aetna unit reported a $900 million surge in unexpected medical costs, leading to its largest one-day share drop in nearly 15 years. As a result, CVS shares have plunged 26% this year, equating to a market cap of just over $70 billion—the same amount it paid for Aetna in 2018. Humana and UnitedHealth have also seen their shares drop by over 20% and 16%, respectively.

Why It Matters?

These changes have rattled investors and corporate boards, signaling a shift from growth to profitability in the Medicare Advantage sector. With the government tightening its purse strings and implementing stricter policies, insurers must adapt quickly. CVS plans to exit some markets and cut back on benefits to improve margins.

Thomas Cowhey, CVS Chief Financial Officer, stated, “The goal for next year is margin over membership.” This shift could open opportunities for companies with better profit margins like UnitedHealth to gain market share. However, the regulatory environment remains a tougher challenge, with tighter payment rates and changes in coding patient risk.

What’s Next?

Insurers are now focusing on mitigating rising costs and adapting to new regulations. Expect strategic exits from less profitable markets and reductions in member benefits. Analysts predict Humana, despite expected lower earnings this year, will rebound to $26 per share by 2026. The industry’s lobbying efforts will intensify to influence public and policymaker opinions.

Wendell Potter, a former Cigna executive, highlighted, “Companies will be investing heavily through campaign donations and lobbying.” A potential Donald Trump win in the upcoming presidential elections could favor privatization and benefit Medicare Advantage. Regardless, the sector remains profitable but without the extraordinary gains seen in recent years.

Source: WSJ
Previous Post

Why Bitcoin’s Correlation with Nasdaq Is Skyrocketing

Next Post

Pharmacy Facelift: How Walgreens and CVS Aim to Boost Profits

Recommended For You

Apple Declares ‘Thermonuclear War’ on OpenAI: Sues Over Trade Secret Theft by Former Design Executive

by Team Lumida
4 hours ago
Apple Store shop front

In one of Tim Cook's final acts before handing the CEO title to John Ternus, Apple filed suit against OpenAI alleging a senior OpenAI executive — who previously...

Read more

US and Iran Trade Multiple Rounds of Strikes Over Strait of Hormuz Control

by Team Lumida
4 hours ago
Iran Tightens Its Grip on Hormuz Despite the Ceasefire — Charging Tolls and Limiting Traffic

The US launched three waves of strikes on Iranian military targets in 24 hours Sunday as Iran fired on commercial vessels in the Strait of Hormuz — deepening...

Read more

352 Million Barrels Drained: Frequent SPR Draws Are Breaking America’s Oil Emergency System

by Team Lumida
4 hours ago
Oil Prices Surge: What Falling US Crude Stocks Mean for Your Investments

The Biden and Trump administrations have released nearly half the Strategic Petroleum Reserve's capacity in just four years — 352 million barrels — to fight high oil prices,...

Read more

Bitcoin Sits Out the War: Crypto Holds Near $63,800 as Gold, Oil, Stocks, and Bonds All Sell Off on Fourth Iran Strike

by Team Lumida
4 hours ago
Bitcoin Could Drop to $50K Before a Potential Fed-Driven Rally

The fourth US strike on Iran in a week sent gold down 1.6%, Brent crude up 4%, Treasuries lower across the curve, and Asian equities down 1.6% —...

Read more

Warsh’s First Big Call: Should the Fed Undo Last Year’s Rate Cuts? He Testifies This Week Without Tipping His Hand

by Team Lumida
4 hours ago
Senate Confirms Kevin Warsh as Fed Chair in Closest Vote Ever

New Federal Reserve Chairman Kevin Warsh presided over a unanimous hold at his first meeting last month, but a steadier economy and stubborn inflation have put a rate...

Read more

How Charles Schwab Turbocharged Trump’s Stock-Trading Frenzy

by Team Lumida
3 days ago
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

After a New York appeals court threw out the ~$500 million penalty from the Letitia James fraud case, Trump's Charles Schwab brokerage account went on an automated trading...

Read more

US Biotechs Are Going Dark to Beat Chinese Copycats — Skipping VC Pitches, Conferences, and Public Filings

by Team Lumida
3 days ago
close-up photo of monitor displaying graph

A growing number of US biotech companies are abandoning standard industry practices — declining VC funding, skipping academic conferences, and avoiding public disclosures — in an effort to...

Read more

US-Iran Nuclear Talks Press On Despite Hormuz Clashes, Oil Spikes 6%

by Team Lumida
3 days ago
people holding us a flag during daytime

Despite two days of US-Iran military strikes that threatened to shatter the mid-June ceasefire — and Trump's suggestion that the deal was 'over' — American officials say technical...

Read more

Goldman Says Carry Trades Face Best Conditions Since 2000 — G10 FX Strategy Returns 8% YTD

by Team Lumida
3 days ago
Goldman Sachs Urges Investors to Cut Risk: Is a Selloff Looming?

Wide and stable interest rate differentials across developed economies, combined with FX volatility near its lowest since 2020, have created the most compelling backdrop for G10 carry trades...

Read more

Polymarket Seeks Futures Commission Merchant License to Offer Margin Trading in the US

by Team Lumida
3 days ago
Indonesia Bans Polymarket After Bets on President Prabowo’s Removal Go Viral

Polymarket filed an application to operate as a futures commission merchant through its affiliate Coming Home GBA LLC, seeking CFTC approval to offer non-fully collateralized trading — following...

Read more
Next Post
woman with face mask holding an alcohol bottle

Pharmacy Facelift: How Walgreens and CVS Aim to Boost Profits

Revolutionizing AI: How DePIN is Solving Robots’ Biggest Blind Spot

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Trump Suggests $2,000 Tariff-Funded Payouts to Americans

Trump Proposes Sweeping Immigration Freeze Targeting “Third World” Countries, Federal Benefits and Status Reviews

November 28, 2025
Amazon’s $100 Billion Bet: AI Over Retail

Hertz to Sell Used Cars Directly to Consumers via Amazon Autos

August 21, 2025
Some Tesla Shareholders Want It to Invest in xAI. The Board Isn’t So Sure.

Some Tesla Shareholders Want It to Invest in xAI. The Board Isn’t So Sure.

November 7, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018